Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.
An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated.
An ENTEROTOXIN from VIBRIO CHOLERAE. It consists of two major protomers, the heavy (H) or A subunit and the B protomer which consists of 5 light (L) or B subunits. The catalytic A subunit is proteolytically cleaved into fragments A1 and A2. The A1 fragment is a MONO(ADP-RIBOSE) TRANSFERASE. The B protomer binds cholera toxin to intestinal epithelial cells, and facilitates the uptake of the A1 fragment. The A1 catalyzed transfer of ADP-RIBOSE to the alpha subunits of heterotrimeric G PROTEINS activates the production of CYCLIC AMP. Increased levels of cyclic AMP are thought to modulate release of fluid and electrolytes from intestinal crypt cells.
The etiologic agent of CHOLERA.
Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.
Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
The giving of drugs, chemicals, or other substances by mouth.
Strains of VIBRIO CHOLERAE containing O ANTIGENS group 1. All are CHOLERA-causing strains (serotypes). There are two biovars (biotypes): cholerae and eltor (El Tor).
Strains of VIBRIO CHOLERAE containing O ANTIGENS group 139. This strain emerged in India in 1992 and caused a CHOLERA epidemic.
The non-susceptibility to infection of a large group of individuals in a population. A variety of factors can be responsible for herd immunity and this gives rise to the different definitions used in the literature. Most commonly, herd immunity refers to the case when, if most of the population is immune, infection of a single individual will not cause an epidemic. Also, in such immunized populations, susceptible individuals are not likely to become infected. Herd immunity can also refer to the case when unprotected individuals fail to contract a disease because the infecting organism has been banished from the population.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
I'm sorry for any confusion, but "Bangladesh" is a country located in South Asia, not a medical term or concept. Therefore, it doesn't have a medical definition. It shares borders with India, Myanmar (Burma), and Bay of Bengal. The population is primarily Bengali, and the official language is Bangla (Bengali). The capital city is Dhaka. If you have any questions related to medicine or health, feel free to ask!
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.
Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.
Two or more vaccines in a single dosage form.
A republic in the Greater Antilles in the West Indies. Its capital is Port-au-Prince. With the Dominican Republic it forms the island of Hispaniola - Haiti occupying the western third and the Dominican Republic, the eastern two thirds. Haiti belonged to France from 1697 until its rule was challenged by slave insurrections from 1791. It became a republic in 1820. It was virtually an American protectorate from 1915 to 1934. It adopted its present constitution in 1964 and amended it in 1971. The name may represent either of two Caribbean words, haiti, mountain land, or jhaiti, nest. (From Webster's New Geographical Dictionary, 1988, p481 & Room, Brewer's Dictionary of Names, 1992, p225)
A republic in western Africa, south of SENEGAL and MALI, east of GUINEA-BISSAU. Its capital is Conakry.
Antisera from immunized animals that is purified and used as a passive immunizing agent against specific BACTERIAL TOXINS.
Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.
Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.
Administration of a vaccine to large populations in order to elicit IMMUNITY.
Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.
I'm sorry for any confusion, but "Pakistan" is a country located in South Asia and it does not have a medical definition. If you have any medical question or term that you would like me to define, please provide it and I will be happy to help.
The development and establishment of environmental conditions favorable to the health of the public.
Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity.
Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.
Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.
I'm sorry for any confusion, but "Philippines" is not a medical term; it is the name of a country located in Southeast Asia. It seems there might be some misunderstanding in your question. If you have a medical query related to the Philippines or its people, I'd be happy to help clarify that for you.
Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.
Persons fleeing to a place of safety, especially those who flee to a foreign country or power to escape danger or persecution in their own country or habitual residence because of race, religion, or political belief. (Webster, 3d ed)
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)
A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)
Vaccines or candidate vaccines containing antigenic polysaccharides from Haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine.
The inhabitants of rural areas or of small towns classified as rural.
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
A republic in eastern Africa, south of UGANDA and north of MOZAMBIQUE. Its capital is Dar es Salaam. It was formed in 1964 by a merger of the countries of TANGANYIKA and ZANZIBAR.
A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.
Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.
Cells of the lymphoid series that can react with antigen to produce specific cell products called antibodies. Various cell subpopulations, often B-lymphocytes, can be defined, based on the different classes of immunoglobulins that they synthesize.
Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS.
A genus of REOVIRIDAE, causing acute gastroenteritis in BIRDS and MAMMALS, including humans. Transmission is horizontal and by environmental contamination. Seven species (Rotaviruses A thru G) are recognized.
Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.
Strains of ESCHERICHIA COLI that produce or contain at least one member of either heat-labile or heat-stable ENTEROTOXINS. The organisms colonize the mucosal surface of the small intestine and elaborate their enterotoxins causing DIARRHEA. They are mainly associated with tropical and developing countries and affect susceptible travelers to those places.

Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama. (1/263)

To provide optimum protection against classical and El Tor biotypes of Vibrio cholerae O1, a single-dose, oral cholera vaccine was developed by combining two live, attenuated vaccine strains, CVD 103-HgR (classical, Inaba) and CVD 111 (El Tor, Ogawa). The vaccines were formulated in a double-chamber sachet; one chamber contained lyophilized bacteria, and the other contained buffer. A total of 170 partially-immune American soldiers stationed in Panama received one of the following five formulations: (a) CVD 103-HgR at 10(8) CFU plus CVD 111 at 10(7) CFU, (b) CVD 103-HgR at 10(8) CFU plus CVD 111 at 10(6) CFU, (c) CVD 103-HgR alone at 10(8) CFU, (d) CVD 111 alone at 10(7) CFU, or (e) inactivated Escherichia coli placebo. Among those who received CVD 111 at the high or low dose either alone or in combination with CVD 103-HgR, 8 of 103 had diarrhea, defined as three or more liquid stools. None of the 32 volunteers who received CVD 103-HgR alone or the 35 placebo recipients had diarrhea. CVD 111 was detected in the stools of 46% of the 103 volunteers who received it. About 65% of all persons who received CVD 103-HgR either alone or in combination had a fourfold rise in Inaba vibriocidal titers. The postvaccination geometric mean titers were comparable among groups, ranging from 450 to 550. Ogawa vibriocidal titers were about twice as high in persons who received CVD 111 as in those who received CVD 103-HgR alone (600 versus 300). The addition of CVD 111 improved the overall seroconversion rate and doubled the serum Ogawa vibriocidal titers, suggesting that the combination of an El Tor and a classical cholera strain is desirable. While CVD 111 was previously found to be well tolerated in semiimmune Peruvians, the adverse effects observed in this study indicate that this strain requires further attenuation before it can be safely used in nonimmune populations.  (+info)

Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. (2/263)

Nasal vaccine delivery is superior to oral delivery in inducing specific immunoglobulin A (IgA) and IgG antibody responses in the upper respiratory tract. Although an antibody response in the nasal passages is important in protecting against primary colonization with lung pathogens, antibodies in the lungs are usually required as well. We immunized 15 male volunteers twice nasally or orally with cholera toxin B subunit (CTB) and determined the specific antibody levels in serum, bronchoalveolar lavage (BAL) fluid, and urine before and 2 weeks after immunization. Nasal immunization induced fivefold increases in the levels of specific IgA antibodies in BAL fluid of most volunteers, whereas there were no significant specific IgA responses after oral immunization. The specific IgG antibody level increased eightfold in BAL fluid in the nasally vaccinated subjects, and the major part of IgG had most probably been transferred from serum. Since the specific IgG response in serum was lower in the individuals vaccinated orally, the IgG response in BAL fluid in this group was also lower and not significant. In conclusion, nasal immunization is also preferable to the oral route when vaccinating against lower respiratory tract infections, and a systemic immune response is considerably more important in the lower than in the upper respiratory tract. Moreover, both nasal and oral immunizations were able to stimulate 6- to 10-fold specific IgA and IgG responses in urine in about half of the individuals, which indicates that distant mucosal vaccination might be used to prevent adhesion of pathogens to the urogenital tract.  (+info)

Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. (3/263)

The mucosal and systemic immune responses after primary and booster immunizations with two attenuated live oral vaccine strains derived from a noninvasive (Vibrio cholerae) and an invasive (Salmonella typhi) enteric pathogen were comparatively evaluated. Vaccination with S. typhi Ty21a elicited antibody-secreting cell (ASC) responses specific for S. typhi O9, 12 lipopolysaccharide (LPS), as well as significant increases in levels of immunoglobulin G (IgG) and IgA antibodies to the same antigen in serum. A strong systemic CD4(+) T-helper type 1 cell-mediated immune (CMI) response was also induced. In contrast to results with Ty21a, no evidence of a CMI response was obtained after primary immunization with V. cholerae CVD 103-HgR in spite of the good immunogenicity of the vaccine. Volunteers who received a single dose of CVD 103-HgR primarily developed an IgM ASC response against whole vaccine cells and purified V. cholerae Inaba LPS, and seroconversion of serum vibriocidal antibodies occurred in four of five subjects. Serum IgG anti-cholera toxin antibody titers were of lower magnitude. For both live vaccines, the volunteers still presented significant local immunity 14 months after primary immunization, as revealed by the elevated baseline antibody titers at the time of the booster immunization and the lower ASC, serum IgG, and vibriocidal antibody responses after the booster immunization. These results suggest that local immunity may interfere with colonization of the gut by both vaccine strains at least up to 14 months after basis immunization. Interestingly, despite a low secondary ASC response, Ty21a was able to boost both humoral (anti-LPS systemic IgG and IgA) and CMI responses. Evidence of a CMI response was also observed for one of three volunteers given a cholera vaccine booster dose. The direct comparison of results with two attenuated live oral vaccine strains in human volunteers clearly showed that the capacity of the vaccine strain to colonize specific body compartments conditions the pattern of vaccine-induced immune responses.  (+info)

Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. (4/263)

Several live oral vaccines (polio, bovine rotavirus, CVD 103-HgR cholera) are less immunogenic in developing than in industrialized countries. It was hypothesized that proximal small bowel bacterial overgrowth (common in children in less developed countries but rare in industrialized settings) diminishes the vibriocidal antibody response to CVD 103-HgR. In total, 202 fasting Santiago schoolchildren aged 5-9 years had lactulose breath H2 tests to detect proximal small bowel bacteria 1 day before ingesting CVD 103-HgR. Florid small bowel overgrowth was observed in 10 (5.6%) of 178 analyzable children. In children with florid overgrowth, vibriocidal seroconversion differed little from other children (60% vs. 67%), but the geometric mean titer was lower (160 vs. 368; P=.25). By logistic regression, increased peak breath H2 at small bowel time points was associated with diminished seroconversion (P=.04), as was the interaction of H2 value and weight (children >25 kg had lower seroconversion rates among subjects with heaviest overgrowth).  (+info)

Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. (5/263)

CVD 103-HgR is a live oral cholera vaccine strain constructed by deleting 94% of the gene for the enzymatically active A subunit of cholera toxin from classical Inaba Vibrio cholerae O1 569B; the strain also contains a mercury resistance gene as an identifying marker. This vaccine was well tolerated and immunogenic in double-blind, controlled studies and was protective in open-label studies of volunteers challenged with V. cholerae O1. A randomized, double-blind, placebo-controlled, multicenter study of vaccine efficacy was designed to test longer-term protection of CVD 103-HgR against moderate and severe El Tor cholera in U.S. volunteers. A total of 85 volunteers (50 at the University of Maryland and 35 at Children's Hospital Medical Center/University of Cincinnati) were recruited for vaccination and challenge with wild-type V. cholerae El Tor Inaba. Volunteers were randomized in a double-blind manner to receive, with buffer, a single oral dose of either CVD 103-HgR (2 x 10(8) to 8 x 10(8) CFU) or placebo (killed E. coli K-12). About 3 months after immunization, 51 of these volunteers were orally challenged with 10(5) CFU of virulent V. cholerae O1 El Tor Inaba strain N16961, prepared from a standardized frozen inoculum. Ninety-one percent of the vaccinees had a >/=4-fold rise in serum vibriocidal antibodies after vaccination. After challenge, 9 (39%) of the 23 placebo recipients and 1 (4%) of the 28 vaccinees had moderate or severe diarrhea (>/=3-liter diarrheal stool) (P < 0.01; protective efficacy, 91%). A total of 21 (91%) of 23 placebo recipients and 5 (18%) of 28 vaccinees had any diarrhea (P < 0.001; protective efficacy, 80%). Peak stool V. cholerae excretion among placebo recipients was 1.1 x 10(7) CFU/g and among vaccinees was 4.9 x 10(2) CFU/g (P < 0.001). This vaccine could therefore be a safe and effective tool to prevent cholera in travelers.  (+info)

Mass vaccination with a two-dose oral cholera vaccine in a refugee camp. (6/263)

In refugee settings, the use of cholera vaccines is controversial since a mass vaccination campaign might disrupt other priority interventions. We therefore conducted a study to assess the feasibility of such a campaign using a two-dose oral cholera vaccine in a refugee camp. The campaign, using killed whole-cell/recombinant B-subunit cholera vaccine, was carried out in October 1997 among 44,000 south Sudanese refugees in Uganda. Outcome variables included the number of doses administered, the drop-out rate between the two rounds, the proportion of vaccine wasted, the speed of administration, the cost of the campaign, and the vaccine coverage. Overall, 63,220 doses of vaccine were administered. At best, 200 vaccine doses were administered per vaccination site and per hour. The direct cost of the campaign amounted to US$ 14,655, not including the vaccine itself. Vaccine coverage, based on vaccination cards, was 83.0% and 75.9% for the first and second rounds, respectively. Mass vaccination of a large refugee population with an oral cholera vaccine therefore proved to be feasible. A pre-emptive vaccination strategy could be considered in stable refugee settings and in urban slums in high-risk areas. However, the potential cost of the vaccine and the absence of quickly accessible stockpiles are major drawbacks for its large-scale use.  (+info)

Optimizing the germfree mouse model for in vivo evaluation of oral Vibrio cholerae vaccine and vector strains. (7/263)

The germfree mouse model of Vibrio cholerae infection can be used to judge immune responses to V. cholerae vaccine and vector strains. In the original model, a single oral inoculation was administered on day 0, a booster oral inoculation was administered on day 14, and immune responses were analyzed with samples collected on day 28. Unfortunately, immune responses in this model frequently were low level, and interanimal variability occurred. In order to improve this model, we evaluated various primary and booster V. cholerae inoculation schedules. The most prominent systemic and mucosal antibody responses were measured in mice that received a multiple primary inoculation series on days 0, 2, 4, and 6 and booster inoculations on days 28 and 42. These modifications result in improved preliminary evaluation of V. cholerae vaccine and vector strains in mice.  (+info)

Use of lambda phage S and R gene products in an inducible lysis system for Vibrio cholerae- and Salmonella enterica serovar typhimurium-based DNA vaccine delivery systems. (8/263)

Novel methods for adapting DNA vaccine technology to the prevention of mucosal diseases are greatly needed. Here we show that regulated expression of phage lambda lysis genes S and R causes dramatic lysis of both Vibrio cholerae and Salmonella enterica serovar Typhimurium cells with concomitant release of plasmid DNA into the surrounding media. We also used single and double DNase mutant strains to show that secreted V. cholerae DNases can adversely affect the integrity of DNA molecules released upon lysis. These results suggest that incorporation of lambda SR-mediated lysis constructs and DNA stabilizing mutations into candidate live attenuated bacterial vaccines offers a promising approach for the development of effective mucosal DNA delivery vectors for humans.  (+info)

Cholera vaccines are preventive measures used to protect against the infection caused by the bacterium Vibrio cholerae. There are several types of cholera vaccines available, including:

1. Inactivated oral vaccine (ICCV): This vaccine contains killed whole-cell bacteria and is given in two doses, with each dose administered at least 14 days apart. It provides protection for up to six months and can be given to adults and children over the age of one year.
2. Live attenuated oral vaccine (LCV): This vaccine contains weakened live bacteria that are unable to cause disease but still stimulate an immune response. The most commonly used LCV is called CVD 103-HgR, which is given in a single dose and provides protection for up to three months. It can be given to adults and children over the age of six years.
3. Injectable cholera vaccine: This vaccine contains inactivated bacteria and is given as an injection. It is not widely available and its effectiveness is limited compared to oral vaccines.

Cholera vaccines are recommended for travelers visiting areas with known cholera outbreaks, particularly if they plan to eat food or drink water that may be contaminated. They can also be used in response to outbreaks to help control the spread of the disease. However, it is important to note that vaccination alone is not sufficient to prevent cholera infection and good hygiene practices, such as handwashing and safe food handling, should always be followed.

Cholera is an infectious disease caused by the bacterium Vibrio cholerae, which is usually transmitted through contaminated food or water. The main symptoms of cholera are profuse watery diarrhea, vomiting, and dehydration, which can lead to electrolyte imbalances, shock, and even death if left untreated. Cholera remains a significant public health concern in many parts of the world, particularly in areas with poor sanitation and hygiene. The disease is preventable through proper food handling, safe water supplies, and improved sanitation, as well as vaccination for those at high risk.

Cholera toxin is a protein toxin produced by the bacterium Vibrio cholerae, which causes the infectious disease cholera. The toxin is composed of two subunits, A and B, and its primary mechanism of action is to alter the normal function of cells in the small intestine.

The B subunit of the toxin binds to ganglioside receptors on the surface of intestinal epithelial cells, allowing the A subunit to enter the cell. Once inside, the A subunit activates a signaling pathway that results in the excessive secretion of chloride ions and water into the intestinal lumen, leading to profuse, watery diarrhea, dehydration, and other symptoms associated with cholera.

Cholera toxin is also used as a research tool in molecular biology and immunology due to its ability to modulate cell signaling pathways. It has been used to study the mechanisms of signal transduction, protein trafficking, and immune responses.

"Vibrio cholerae" is a species of gram-negative, comma-shaped bacteria that is the causative agent of cholera, a diarrheal disease. It can be found in aquatic environments, such as estuaries and coastal waters, and can sometimes be present in raw or undercooked seafood. The bacterium produces a toxin called cholera toxin, which causes the profuse, watery diarrhea that is characteristic of cholera. In severe cases, cholera can lead to dehydration and electrolyte imbalances, which can be life-threatening if not promptly treated with oral rehydration therapy or intravenous fluids.

Inactivated vaccines, also known as killed or non-live vaccines, are created by using a version of the virus or bacteria that has been grown in a laboratory and then killed or inactivated with chemicals, heat, or radiation. This process renders the organism unable to cause disease, but still capable of stimulating an immune response when introduced into the body.

Inactivated vaccines are generally considered safer than live attenuated vaccines since they cannot revert back to a virulent form and cause illness. However, they may require multiple doses or booster shots to maintain immunity because the immune response generated by inactivated vaccines is not as robust as that produced by live vaccines. Examples of inactivated vaccines include those for hepatitis A, rabies, and influenza (inactivated flu vaccine).

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. It typically contains an agent that resembles the disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it encounters in the future.

Vaccines can be prophylactic (to prevent or ameliorate the effects of a future infection by a natural or "wild" pathogen), or therapeutic (to fight disease that is already present). The administration of vaccines is called vaccination. Vaccinations are generally administered through needle injections, but can also be administered by mouth or sprayed into the nose.

The term "vaccine" comes from Edward Jenner's 1796 use of cowpox to create immunity to smallpox. The first successful vaccine was developed in 1796 by Edward Jenner, who showed that milkmaids who had contracted cowpox did not get smallpox. He reasoned that exposure to cowpox protected against smallpox and tested his theory by injecting a boy with pus from a cowpox sore and then exposing him to smallpox, which the boy did not contract. The word "vaccine" is derived from Variolae vaccinae (smallpox of the cow), the term devised by Jenner to denote cowpox. He used it in 1798 during a conversation with a fellow physician and later in the title of his 1801 Inquiry.

Vaccination is a simple, safe, and effective way to protect people against harmful diseases, before they come into contact with them. It uses your body's natural defenses to build protection to specific infections and makes your immune system stronger.

A vaccination usually contains a small, harmless piece of a virus or bacteria (or toxins produced by these germs) that has been made inactive or weakened so it won't cause the disease itself. This piece of the germ is known as an antigen. When the vaccine is introduced into the body, the immune system recognizes the antigen as foreign and produces antibodies to fight it.

If a person then comes into contact with the actual disease-causing germ, their immune system will recognize it and immediately produce antibodies to destroy it. The person is therefore protected against that disease. This is known as active immunity.

Vaccinations are important for both individual and public health. They prevent the spread of contagious diseases and protect vulnerable members of the population, such as young children, the elderly, and people with weakened immune systems who cannot be vaccinated or for whom vaccination is not effective.

Oral administration is a route of giving medications or other substances by mouth. This can be in the form of tablets, capsules, liquids, pastes, or other forms that can be swallowed. Once ingested, the substance is absorbed through the gastrointestinal tract and enters the bloodstream to reach its intended target site in the body. Oral administration is a common and convenient route of medication delivery, but it may not be appropriate for all substances or in certain situations, such as when rapid onset of action is required or when the patient has difficulty swallowing.

"Vibrio cholerae O1" is a specific serogroup of the bacterium Vibrio cholerae that is responsible for causing cholera, a diarrheal disease. The "O1" designation refers to the lipopolysaccharide (O) antigen present on the surface of the bacterial cell wall, which is used in the serological classification of Vibrio cholerae. This serogroup is further divided into two biotypes: classical and El Tor. The El Tor biotype has been responsible for the seventh pandemic of cholera that began in the late 1960s and continues to cause outbreaks in many parts of the world today.

The Vibrio cholerae O1 bacterium produces a potent enterotoxin called cholera toxin, which causes profuse watery diarrhea leading to rapid dehydration and electrolyte imbalance if left untreated. The infection is usually acquired through the ingestion of contaminated food or water. Preventive measures include improving access to safe drinking water, proper sanitation, and good hygiene practices.

"Vibrio cholerae O139" is a specific serogroup of the bacterium Vibrio cholerae, which is responsible for causing cholera, a diarrheal disease. The "O139" designation refers to the lipopolysaccharide antigen structure on the surface of the bacterial cell. This serogroup was first identified in 1992 in southern Asia and has since caused several outbreaks of cholera, particularly in that region. It is important to note that "Vibrio cholerae O139" is distinct from the more common "Vibrio cholerae O1," which has historically been responsible for most cholera cases worldwide. Both serogroups can cause severe diarrhea and dehydration if left untreated, but "Vibrio cholerae O139" is typically associated with a milder illness compared to "Vibrio cholerae O1."

Herd immunity, also known as community immunity or population immunity, is a form of indirect protection from infectious diseases that occurs when a large percentage of a population has become immune to an infection, either through vaccination or previous illness. This reduces the likelihood of infection for individuals who are not immune, especially those who cannot receive vaccines due to medical reasons. The more people in a community who are immune, the less likely the disease will spread and the entire community is protected, not just those who are immune.

Synthetic vaccines are artificially produced, designed to stimulate an immune response and provide protection against specific diseases. Unlike traditional vaccines that are derived from weakened or killed pathogens, synthetic vaccines are created using synthetic components, such as synthesized viral proteins, DNA, or RNA. These components mimic the disease-causing agent and trigger an immune response without causing the actual disease. The use of synthetic vaccines offers advantages in terms of safety, consistency, and scalability in production, making them valuable tools for preventing infectious diseases.

I'm sorry for any confusion, but "Bangladesh" is a country located in South Asia, rather than a medical term or condition. It is bordered by India to the west, north, and east, and by Myanmar (Burma) to the southeast, with the Bay of Bengal to the south. The official name of the country is the People's Republic of Bangladesh.

If you have any questions related to medical terminology or health-related topics, I would be happy to help answer them for you!

A viral vaccine is a biological preparation that introduces your body to a specific virus in a way that helps your immune system build up protection against the virus without causing the illness. Viral vaccines can be made from weakened or inactivated forms of the virus, or parts of the virus such as proteins or sugars. Once introduced to the body, the immune system recognizes the virus as foreign and produces an immune response, including the production of antibodies. These antibodies remain in the body and provide immunity against future infection with that specific virus.

Viral vaccines are important tools for preventing infectious diseases caused by viruses, such as influenza, measles, mumps, rubella, polio, hepatitis A and B, rabies, rotavirus, chickenpox, shingles, and some types of cancer. Vaccination programs have led to the control or elimination of many infectious diseases that were once common.

It's important to note that viral vaccines are not effective against bacterial infections, and separate vaccines must be developed for each type of virus. Additionally, because viruses can mutate over time, it is necessary to update some viral vaccines periodically to ensure continued protection.

Bacterial antibodies are a type of antibodies produced by the immune system in response to an infection caused by bacteria. These antibodies are proteins that recognize and bind to specific antigens on the surface of the bacterial cells, marking them for destruction by other immune cells. Bacterial antibodies can be classified into several types based on their structure and function, including IgG, IgM, IgA, and IgE. They play a crucial role in the body's defense against bacterial infections and provide immunity to future infections with the same bacteria.

I could not find a specific medical definition for "Vaccines, DNA." However, I can provide you with some information about DNA vaccines.

DNA vaccines are a type of vaccine that uses genetically engineered DNA to stimulate an immune response in the body. They work by introducing a small piece of DNA into the body that contains the genetic code for a specific antigen (a substance that triggers an immune response). The cells of the body then use this DNA to produce the antigen, which prompts the immune system to recognize and attack it.

DNA vaccines have several advantages over traditional vaccines. They are relatively easy to produce, can be stored at room temperature, and can be designed to protect against a wide range of diseases. Additionally, because they use DNA to stimulate an immune response, DNA vaccines do not require the growth and culture of viruses or bacteria, which can make them safer than traditional vaccines.

DNA vaccines are still in the experimental stages, and more research is needed to determine their safety and effectiveness. However, they have shown promise in animal studies and are being investigated as a potential tool for preventing a variety of infectious diseases, including influenza, HIV, and cancer.

Bacterial vaccines are types of vaccines that are created using bacteria or parts of bacteria as the immunogen, which is the substance that triggers an immune response in the body. The purpose of a bacterial vaccine is to stimulate the immune system to develop protection against specific bacterial infections.

There are several types of bacterial vaccines, including:

1. Inactivated or killed whole-cell vaccines: These vaccines contain entire bacteria that have been killed or inactivated through various methods, such as heat or chemicals. The bacteria can no longer cause disease, but they still retain the ability to stimulate an immune response.
2. Subunit, protein, or polysaccharide vaccines: These vaccines use specific components of the bacterium, such as proteins or polysaccharides, that are known to trigger an immune response. By using only these components, the vaccine can avoid using the entire bacterium, which may reduce the risk of adverse reactions.
3. Live attenuated vaccines: These vaccines contain live bacteria that have been weakened or attenuated so that they cannot cause disease but still retain the ability to stimulate an immune response. This type of vaccine can provide long-lasting immunity, but it may not be suitable for people with weakened immune systems.

Bacterial vaccines are essential tools in preventing and controlling bacterial infections, reducing the burden of diseases such as tuberculosis, pneumococcal disease, meningococcal disease, and Haemophilus influenzae type b (Hib) disease. They work by exposing the immune system to a harmless form of the bacteria or its components, which triggers the production of antibodies and memory cells that can recognize and fight off future infections with that same bacterium.

It's important to note that while vaccines are generally safe and effective, they may cause mild side effects such as pain, redness, or swelling at the injection site, fever, or fatigue. Serious side effects are rare but can occur, so it's essential to consult with a healthcare provider before receiving any vaccine.

Combined vaccines are defined in medical terms as vaccines that contain two or more antigens from different diseases, which are given to provide protection against multiple diseases at the same time. This approach reduces the number of injections required and simplifies the immunization schedule, especially during early childhood. Examples of combined vaccines include:

1. DTaP-Hib-IPV (e.g., Pentacel): A vaccine that combines diphtheria, tetanus, pertussis (whooping cough), Haemophilus influenzae type b (Hib) disease, and poliovirus components in one injection to protect against these five diseases.
2. MMRV (e.g., ProQuad): A vaccine that combines measles, mumps, rubella, and varicella (chickenpox) antigens in a single injection to provide immunity against all four diseases.
3. HepA-HepB (e.g., Twinrix): A vaccine that combines hepatitis A and hepatitis B antigens in one injection, providing protection against both types of hepatitis.
4. MenACWY-TT (e.g., MenQuadfi): A vaccine that combines four serogroups of meningococcal bacteria (A, C, W, Y) with tetanus toxoid as a carrier protein in one injection for the prevention of invasive meningococcal disease caused by these serogroups.
5. PCV13-PPSV23 (e.g., Vaxneuvance): A vaccine that combines 13 pneumococcal serotypes with PPSV23, providing protection against a broader range of pneumococcal diseases in adults aged 18 years and older.

Combined vaccines have been thoroughly tested for safety and efficacy to ensure they provide a strong immune response and an acceptable safety profile. They are essential tools in preventing various infectious diseases and improving overall public health.

I'm sorry for any confusion, but "Haiti" is not a medical term. It is a country located in the Caribbean, specifically on the island of Hispaniola. If you have any questions about medical conditions or terminology, I would be happy to help clarify those for you.

I'm sorry for any confusion, but "Guinea" is not a medical term. It is a geographical term referring to a region on the west coast of Africa, as well as the country of Equatorial Guinea and its neighboring countries. Additionally, "Guinea" can also refer to a unit of currency in Liberia.

If you have any medical concerns or questions, I would be happy to try to help answer them for you.

Antitoxins are substances, typically antibodies, that neutralize toxins produced by bacteria or other harmful organisms. They work by binding to the toxin molecules and rendering them inactive, preventing them from causing harm to the body. Antitoxins can be produced naturally by the immune system during an infection, or they can be administered artificially through immunization or passive immunotherapy. In a medical context, antitoxins are often used as a treatment for certain types of bacterial infections, such as diphtheria and botulism, to help counteract the effects of the toxins produced by the bacteria.

An AIDS vaccine is a type of preventive vaccine that aims to stimulate the immune system to produce an effective response against the human immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome (AIDS). The goal of an AIDS vaccine is to induce the production of immune cells and proteins that can recognize and eliminate HIV-infected cells, thereby preventing the establishment of a persistent infection.

Despite decades of research, there is still no licensed AIDS vaccine available. This is due in part to the unique challenges posed by HIV, which has a high mutation rate and can rapidly evolve to evade the immune system's defenses. However, several promising vaccine candidates are currently being tested in clinical trials around the world, and researchers continue to explore new approaches and strategies for developing an effective AIDS vaccine.

A subunit vaccine is a type of vaccine that contains a specific piece or component of the microorganism (such as a protein, sugar, or part of the bacterial outer membrane), instead of containing the entire organism. This piece of the microorganism is known as an antigen, and it stimulates an immune response in the body, allowing the development of immunity against the targeted infection without introducing the risk of disease associated with live vaccines.

Subunit vaccines offer several advantages over other types of vaccines. They are generally safer because they do not contain live or weakened microorganisms, making them suitable for individuals with weakened immune systems or specific medical conditions that prevent them from receiving live vaccines. Additionally, subunit vaccines can be designed to focus on the most immunogenic components of a pathogen, potentially leading to stronger and more targeted immune responses.

Examples of subunit vaccines include the Hepatitis B vaccine, which contains a viral protein, and the Haemophilus influenzae type b (Hib) vaccine, which uses pieces of the bacterial polysaccharide capsule. These vaccines have been crucial in preventing serious infectious diseases and reducing associated complications worldwide.

Mass vaccination is a coordinated effort to administer vaccine doses to a large portion of a population in a short amount of time. This strategy is often used during outbreaks of infectious diseases, such as influenza or measles, to quickly build up community immunity (herd immunity) and reduce the spread of the disease. Mass vaccination campaigns can also be implemented as part of public health initiatives to control or eliminate vaccine-preventable diseases in a population. These campaigns typically involve mobilizing healthcare workers, volunteers, and resources to reach and vaccinate as many people as possible, often through mobile clinics, community centers, and other accessible locations.

Conjugate vaccines are a type of vaccine that combines a part of a bacterium with a protein or other substance to boost the body's immune response to the bacteria. The bacterial component is usually a polysaccharide, which is a long chain of sugars that makes up part of the bacterial cell wall.

By itself, a polysaccharide is not very immunogenic, meaning it does not stimulate a strong immune response. However, when it is conjugated or linked to a protein or other carrier molecule, it becomes much more immunogenic and can elicit a stronger and longer-lasting immune response.

Conjugate vaccines are particularly effective in protecting against bacterial infections that affect young children, such as Haemophilus influenzae type b (Hib) and pneumococcal disease. These vaccines have been instrumental in reducing the incidence of these diseases and their associated complications, such as meningitis and pneumonia.

Overall, conjugate vaccines work by mimicking a natural infection and stimulating the immune system to produce antibodies that can protect against future infections with the same bacterium. By combining a weakly immunogenic polysaccharide with a protein carrier, these vaccines can elicit a stronger and more effective immune response, providing long-lasting protection against bacterial infections.

I'm sorry for any confusion, but "Pakistan" is a country in South Asia and not a medical term or condition. If you have any medical questions or terms you would like defined, I would be happy to help!

Sanitation is the provision of facilities and services for the safe disposal of human feces and urine, and the cleaning of homes, workplaces, streets, and other spaces where people live and work. This includes the collection, transport, treatment, and disposal or reuse of human waste, as well as the maintenance of hygienic conditions in these areas to prevent the spread of diseases.

The World Health Organization (WHO) defines sanitation as "the use of toilets or latrines that safely dispose of human waste, as well as the safe management of human waste at the household, community, and national levels." Sanitation is an essential component of public health and is critical for preventing the spread of infectious diseases such as cholera, typhoid, hepatitis A, and polio.

Poor sanitation can have serious consequences for individuals and communities, including increased risk of disease and death, decreased productivity, reduced economic growth, and negative impacts on social and mental well-being. Providing access to safe sanitation is a key target of the United Nations Sustainable Development Goals (SDGs), with a goal to ensure that everyone has access to adequate and equitable sanitation by 2030.

Attenuated vaccines consist of live microorganisms that have been weakened (attenuated) through various laboratory processes so they do not cause disease in the majority of recipients but still stimulate an immune response. The purpose of attenuation is to reduce the virulence or replication capacity of the pathogen while keeping it alive, allowing it to retain its antigenic properties and induce a strong and protective immune response.

Examples of attenuated vaccines include:

1. Sabin oral poliovirus vaccine (OPV): This vaccine uses live but weakened polioviruses to protect against all three strains of the disease-causing poliovirus. The weakened viruses replicate in the intestine and induce an immune response, which provides both humoral (antibody) and cell-mediated immunity.
2. Measles, mumps, and rubella (MMR) vaccine: This combination vaccine contains live attenuated measles, mumps, and rubella viruses. It is given to protect against these three diseases and prevent their spread in the population.
3. Varicella (chickenpox) vaccine: This vaccine uses a weakened form of the varicella-zoster virus, which causes chickenpox. By introducing this attenuated virus into the body, it stimulates an immune response that protects against future infection with the wild-type virus.
4. Yellow fever vaccine: This live attenuated vaccine is used to prevent yellow fever, a viral disease transmitted by mosquitoes in tropical and subtropical regions of Africa and South America. The vaccine contains a weakened form of the yellow fever virus that cannot cause the disease but still induces an immune response.
5. Bacillus Calmette-Guérin (BCG) vaccine: This live attenuated vaccine is used to protect against tuberculosis (TB). It contains a weakened strain of Mycobacterium bovis, which does not cause TB in humans but stimulates an immune response that provides some protection against the disease.

Attenuated vaccines are generally effective at inducing long-lasting immunity and can provide robust protection against targeted diseases. However, they may pose a risk for individuals with weakened immune systems, as the attenuated viruses or bacteria could potentially cause illness in these individuals. Therefore, it is essential to consider an individual's health status before administering live attenuated vaccines.

Malaria vaccines are biological preparations that induce immunity against malaria parasites, thereby preventing or reducing the severity of malaria disease. They typically contain antigens (proteins or other molecules derived from the parasite) that stimulate an immune response in the recipient, enabling their body to recognize and neutralize the pathogen upon exposure.

The most advanced malaria vaccine candidate is RTS,S/AS01 (Mosquirix), which targets the Plasmodium falciparum parasite's circumsporozoite protein (CSP). This vaccine has shown partial protection in clinical trials, reducing the risk of severe malaria and hospitalization in young children by about 30% over four years. However, it does not provide complete immunity, and additional research is ongoing to develop more effective vaccines against malaria.

Immunization is defined medically as the process where an individual is made immune or resistant to an infectious disease, typically through the administration of a vaccine. The vaccine stimulates the body's own immune system to recognize and fight off the specific disease-causing organism, thereby preventing or reducing the severity of future infections with that organism.

Immunization can be achieved actively, where the person is given a vaccine to trigger an immune response, or passively, where antibodies are transferred to the person through immunoglobulin therapy. Immunizations are an important part of preventive healthcare and have been successful in controlling and eliminating many infectious diseases worldwide.

Immunologic adjuvants are substances that are added to a vaccine to enhance the body's immune response to the antigens contained in the vaccine. They work by stimulating the immune system and promoting the production of antibodies and activating immune cells, such as T-cells and macrophages, which help to provide a stronger and more sustained immune response to the vaccine.

Immunologic adjuvants can be derived from various sources, including bacteria, viruses, and chemicals. Some common examples include aluminum salts (alum), oil-in-water emulsions (such as MF59), and bacterial components (such as lipopolysaccharide or LPS).

The use of immunologic adjuvants in vaccines can help to improve the efficacy of the vaccine, particularly for vaccines that contain weak or poorly immunogenic antigens. They can also help to reduce the amount of antigen needed in a vaccine, which can be beneficial for vaccines that are difficult or expensive to produce.

It's important to note that while adjuvants can enhance the immune response to a vaccine, they can also increase the risk of adverse reactions, such as inflammation and pain at the injection site. Therefore, the use of immunologic adjuvants must be carefully balanced against their potential benefits and risks.

Papillomavirus vaccines are vaccines that have been developed to prevent infection by human papillomaviruses (HPV). HPV is a DNA virus that is capable of infecting the skin and mucous membranes. Certain types of HPV are known to cause cervical cancer, as well as other types of cancer such as anal, penile, vulvar, and oropharyngeal cancers. Other types of HPV can cause genital warts.

There are currently two papillomavirus vaccines that have been approved for use in the United States: Gardasil and Cervarix. Both vaccines protect against the two most common cancer-causing types of HPV (types 16 and 18), which together cause about 70% of cervical cancers. Gardasil also protects against the two most common types of HPV that cause genital warts (types 6 and 11).

Papillomavirus vaccines are given as a series of three shots over a period of six months. They are most effective when given to people before they become sexually active, as this reduces the risk of exposure to HPV. The Centers for Disease Control and Prevention (CDC) recommends that all boys and girls get vaccinated against HPV at age 11 or 12, but the vaccine can be given to people as young as age 9 and as old as age 26.

It is important to note that papillomavirus vaccines do not protect against all types of HPV, and they do not treat existing HPV infections or cervical cancer. They are intended to prevent new HPV infections and the cancers and other diseases that can be caused by HPV.

Meningococcal vaccines are vaccines that protect against Neisseria meningitidis, a type of bacteria that can cause serious infections such as meningitis (inflammation of the lining of the brain and spinal cord) and septicemia (bloodstream infection). There are several types of meningococcal vaccines available, including conjugate vaccines and polysaccharide vaccines. These vaccines work by stimulating the immune system to produce antibodies that can protect against the different serogroups of N. meningitidis, including A, B, C, Y, and W-135. The specific type of vaccine used and the number of doses required may depend on a person's age, health status, and other factors. Meningococcal vaccines are recommended for certain high-risk populations, such as infants, young children, adolescents, and people with certain medical conditions, as well as for travelers to areas where meningococcal disease is common.

I'm sorry for any confusion, but "Philippines" is not a medical term. It is the name of a country located in Southeast Asia, comprised of over 7,000 islands. If you have any questions about medical conditions or terms, I would be happy to help clarify those for you.

Immunoglobulin A (IgA) is a type of antibody that plays a crucial role in the immune function of the human body. It is primarily found in external secretions, such as saliva, tears, breast milk, and sweat, as well as in mucous membranes lining the respiratory and gastrointestinal tracts. IgA exists in two forms: a monomeric form found in serum and a polymeric form found in secretions.

The primary function of IgA is to provide immune protection at mucosal surfaces, which are exposed to various environmental antigens, such as bacteria, viruses, parasites, and allergens. By doing so, it helps prevent the entry and colonization of pathogens into the body, reducing the risk of infections and inflammation.

IgA functions by binding to antigens present on the surface of pathogens or allergens, forming immune complexes that can neutralize their activity. These complexes are then transported across the epithelial cells lining mucosal surfaces and released into the lumen, where they prevent the adherence and invasion of pathogens.

In summary, Immunoglobulin A (IgA) is a vital antibody that provides immune defense at mucosal surfaces by neutralizing and preventing the entry of harmful antigens into the body.

Antibody formation, also known as humoral immune response, is the process by which the immune system produces proteins called antibodies in response to the presence of a foreign substance (antigen) in the body. This process involves several steps:

1. Recognition: The antigen is recognized and bound by a type of white blood cell called a B lymphocyte or B cell, which then becomes activated.
2. Differentiation: The activated B cell undergoes differentiation to become a plasma cell, which is a type of cell that produces and secretes large amounts of antibodies.
3. Antibody production: The plasma cells produce and release antibodies, which are proteins made up of four polypeptide chains (two heavy chains and two light chains) arranged in a Y-shape. Each antibody has two binding sites that can recognize and bind to specific regions on the antigen called epitopes.
4. Neutralization or elimination: The antibodies bind to the antigens, neutralizing them or marking them for destruction by other immune cells. This helps to prevent the spread of infection and protect the body from harmful substances.

Antibody formation is an important part of the adaptive immune response, which allows the body to specifically recognize and respond to a wide variety of pathogens and foreign substances.

Immunoglobulin G (IgG) is a type of antibody, which is a protective protein produced by the immune system in response to foreign substances like bacteria or viruses. IgG is the most abundant type of antibody in human blood, making up about 75-80% of all antibodies. It is found in all body fluids and plays a crucial role in fighting infections caused by bacteria, viruses, and toxins.

IgG has several important functions:

1. Neutralization: IgG can bind to the surface of bacteria or viruses, preventing them from attaching to and infecting human cells.
2. Opsonization: IgG coats the surface of pathogens, making them more recognizable and easier for immune cells like neutrophils and macrophages to phagocytose (engulf and destroy) them.
3. Complement activation: IgG can activate the complement system, a group of proteins that work together to help eliminate pathogens from the body. Activation of the complement system leads to the formation of the membrane attack complex, which creates holes in the cell membranes of bacteria, leading to their lysis (destruction).
4. Antibody-dependent cellular cytotoxicity (ADCC): IgG can bind to immune cells like natural killer (NK) cells and trigger them to release substances that cause target cells (such as virus-infected or cancerous cells) to undergo apoptosis (programmed cell death).
5. Immune complex formation: IgG can form immune complexes with antigens, which can then be removed from the body through various mechanisms, such as phagocytosis by immune cells or excretion in urine.

IgG is a critical component of adaptive immunity and provides long-lasting protection against reinfection with many pathogens. It has four subclasses (IgG1, IgG2, IgG3, and IgG4) that differ in their structure, function, and distribution in the body.

"Hepatitis B vaccines are vaccines that prevent infection caused by the hepatitis B virus. They work by introducing a small and harmless piece of the virus to your body, which triggers your immune system to produce antibodies to fight off the infection. These antibodies remain in your body and provide protection if you are exposed to the real hepatitis B virus in the future.

The hepatitis B vaccine is typically given as a series of three shots over a six-month period. It is recommended for all infants, children and adolescents who have not previously been vaccinated, as well as for adults who are at increased risk of infection, such as healthcare workers, people who inject drugs, and those with certain medical conditions.

It's important to note that hepatitis B vaccine does not provide protection against other types of viral hepatitis, such as hepatitis A or C."

Medically, the term "refugees" does not have a specific definition. However, in a broader social and humanitarian context, refugees are defined by the United Nations as:

"People who are outside their country of nationality or habitual residence; have a well-founded fear of persecution because of their race, religion, nationality, membership in a particular social group or political opinion; and are unable or unwilling to avail themselves of the protection of that country, or to return there, for fear of persecution."

Refugees often face significant health challenges due to forced displacement, violence, trauma, limited access to healthcare services, and harsh living conditions. They may experience physical and mental health issues, including infectious diseases, malnutrition, depression, anxiety, and post-traumatic stress disorder (PTSD). Providing medical care and support for refugees is an important aspect of global public health.

Diarrhea is a condition in which an individual experiences loose, watery stools frequently, often exceeding three times a day. It can be acute, lasting for several days, or chronic, persisting for weeks or even months. Diarrhea can result from various factors, including viral, bacterial, or parasitic infections, food intolerances, medications, and underlying medical conditions such as inflammatory bowel disease or irritable bowel syndrome. Dehydration is a potential complication of diarrhea, particularly in severe cases or in vulnerable populations like young children and the elderly.

A measles vaccine is a biological preparation that induces immunity against the measles virus. It contains an attenuated (weakened) strain of the measles virus, which stimulates the immune system to produce antibodies that protect against future infection with the wild-type (disease-causing) virus. Measles vaccines are typically administered in combination with vaccines against mumps and rubella (German measles), forming the MMR vaccine.

The measles vaccine is highly effective, with one or two doses providing immunity in over 95% of people who receive it. It is usually given to children as part of routine childhood immunization programs, with the first dose administered at 12-15 months of age and the second dose at 4-6 years of age.

Measles vaccination has led to a dramatic reduction in the incidence of measles worldwide and is considered one of the greatest public health achievements of the past century. However, despite widespread availability of the vaccine, measles remains a significant cause of morbidity and mortality in some parts of the world, particularly in areas with low vaccination coverage or where access to healthcare is limited.

A Pertussis vaccine is a type of immunization used to protect against pertussis, also known as whooping cough. It contains components that stimulate the immune system to produce antibodies against the bacteria that cause pertussis, Bordetella pertussis. There are two main types of pertussis vaccines: whole-cell pertussis (wP) vaccines and acellular pertussis (aP) vaccines. wP vaccines contain killed whole cells of B. pertussis, while aP vaccines contain specific components of the bacteria, such as pertussis toxin and other antigens. Pertussis vaccines are often combined with diphtheria and tetanus to form combination vaccines, such as DTaP (diphtheria, tetanus, and acellular pertussis) and TdaP (tetanus, diphtheria, and acellular pertussis). These vaccines are typically given to young children as part of their routine immunization schedule.

Haemophilus vaccines are vaccines that are designed to protect against Haemophilus influenzae type b (Hib), a bacterium that can cause serious infections such as meningitis, pneumonia, and epiglottitis. There are two main types of Hib vaccines:

1. Polysaccharide vaccine: This type of vaccine is made from the sugar coating (polysaccharide) of the bacterial cells. It is not effective in children under 2 years of age because their immune systems are not yet mature enough to respond effectively to this type of vaccine.
2. Conjugate vaccine: This type of vaccine combines the polysaccharide with a protein carrier, which helps to stimulate a stronger and more sustained immune response. It is effective in infants as young as 6 weeks old.

Hib vaccines are usually given as part of routine childhood immunizations starting at 2 months of age. They are administered through an injection into the muscle. The vaccine is safe and effective, with few side effects. Vaccination against Hib has led to a significant reduction in the incidence of Hib infections worldwide.

A rural population refers to people who live in areas that are outside of urban areas, typically defined as having fewer than 2,000 residents and lacking certain infrastructure and services such as running water, sewage systems, and paved roads. Rural populations often have less access to healthcare services, education, and economic opportunities compared to their urban counterparts. This population group can face unique health challenges, including higher rates of poverty, limited access to specialized medical care, and a greater exposure to environmental hazards such as agricultural chemicals and industrial pollutants.

BCG (Bacillus Calmette-Guérin) vaccine is a type of immunization used primarily to prevent tuberculosis (TB). It contains a live but weakened strain of Mycobacterium bovis, which is related to the bacterium that causes TB in humans (Mycobacterium tuberculosis).

The BCG vaccine works by stimulating an immune response in the body, enabling it to better resist infection with TB bacteria if exposed in the future. It is often given to infants and children in countries where TB is common, and its use varies depending on the national immunization policies. The protection offered by the BCG vaccine is moderate and may not last for a very long time.

In addition to its use against TB, the BCG vaccine has also been investigated for its potential therapeutic role in treating bladder cancer and some other types of cancer. The mechanism of action in these cases is thought to be related to the vaccine's ability to stimulate an immune response against abnormal cells.

I'm sorry for any confusion, but "Tanzania" is not a medical term. It is the name of a country located in East Africa. If you have any questions about medical terms or conditions, I would be happy to help clarify those for you.

Poliovirus Vaccine, Inactivated (IPV) is a vaccine used to prevent poliomyelitis (polio), a highly infectious disease caused by the poliovirus. IPV contains inactivated (killed) polioviruses of all three poliovirus types. It works by stimulating an immune response in the body, but because the viruses are inactivated, they cannot cause polio. After vaccination, the immune system recognizes and responds to the inactivated viruses, producing antibodies that protect against future infection with wild, or naturally occurring, polioviruses. IPV is typically given as an injection in the leg or arm, and a series of doses are required for full protection. It is a safe and effective way to prevent polio and its complications.

Rabies vaccines are medical products that contain antigens of the rabies virus, which stimulate an immune response in individuals who receive them. The purpose of rabies vaccines is to prevent the development of rabies, a viral disease that is almost always fatal once symptoms appear.

There are two primary types of rabies vaccines available:

1. Pre-exposure prophylaxis (PrEP) vaccines: These vaccines are given to individuals who are at high risk of coming into contact with the rabies virus, such as veterinarians, animal handlers, and travelers visiting areas where rabies is common. The vaccine series typically consists of three doses given over a period of 28 days.
2. Post-exposure prophylaxis (PEP) vaccines: These vaccines are administered to individuals who have already been exposed to the rabies virus, usually through a bite or scratch from an infected animal. The vaccine series typically consists of four doses given over a period of 14 days, along with a dose of rabies immune globulin (RIG) to provide immediate protection while the immune system responds to the vaccine.

Both types of rabies vaccines are highly effective at preventing the disease, but it is essential to receive them as soon as possible after exposure or before potential exposure, as the virus can be fatal if left untreated.

Antibody-producing cells, also known as plasma cells, are a type of white blood cell that is responsible for producing and secreting antibodies in response to a foreign substance or antigen. These cells are derived from B lymphocytes, which become activated upon encountering an antigen and differentiate into plasma cells.

Once activated, plasma cells can produce large amounts of specific antibodies that bind to the antigen, marking it for destruction by other immune cells. Antibody-producing cells play a crucial role in the body's humoral immune response, which helps protect against infection and disease.

Rotavirus vaccines are preventive measures used to protect against rotavirus infections, which are the leading cause of severe diarrhea and dehydration among infants and young children worldwide. These vaccines contain weakened or inactivated forms of the rotavirus, a pathogen that infects and causes symptoms by multiplying inside cells lining the small intestine.

The weakened or inactivated virus in the vaccine stimulates an immune response in the body, enabling it to recognize and fight off future rotavirus infections more effectively. The vaccines are usually administered orally, as a liquid droplet or on a sugar cube, to mimic natural infection through the gastrointestinal tract.

There are currently two licensed rotavirus vaccines available globally:

1. Rotarix (GlaxoSmithKline): This vaccine contains an attenuated (weakened) strain of human rotavirus and is given in a two-dose series, typically at 2 and 4 months of age.
2. RotaTeq (Merck): This vaccine contains five reassortant viruses, combining human and animal strains to provide broader protection. It is administered in a three-dose series, usually at 2, 4, and 6 months of age.

Rotavirus vaccines have been shown to significantly reduce the incidence of severe rotavirus gastroenteritis and related hospitalizations among infants and young children. The World Health Organization (WHO) recommends the inclusion of rotavirus vaccination in national immunization programs, particularly in countries with high child mortality rates due to diarrheal diseases.

Rotavirus is a genus of double-stranded RNA virus in the Reoviridae family, which is a leading cause of severe diarrhea and gastroenteritis in young children and infants worldwide. The virus infects and damages the cells lining the small intestine, resulting in symptoms such as vomiting, watery diarrhea, abdominal cramps, and fever.

Rotavirus is highly contagious and can be spread through contact with infected individuals or contaminated surfaces, food, or water. The virus is typically transmitted via the fecal-oral route, meaning that it enters the body through the mouth after coming into contact with contaminated hands, objects, or food.

Rotavirus infections are often self-limiting and resolve within a few days to a week, but severe cases can lead to dehydration, hospitalization, and even death, particularly in developing countries where access to medical care and rehydration therapy may be limited. Fortunately, there are effective vaccines available that can prevent rotavirus infection and reduce the severity of symptoms in those who do become infected.

According to the World Health Organization (WHO), Rotavirus is the most common cause of severe diarrhea among children under 5 years of age. It is responsible for around 215,000 deaths among children in this age group each year.

Rotavirus infection causes inflammation of the stomach and intestines, resulting in symptoms such as vomiting, watery diarrhea, and fever. The virus is transmitted through the fecal-oral route, often through contaminated hands, food, or water. It can also be spread through respiratory droplets when an infected person coughs or sneezes.

Rotavirus infections are highly contagious and can spread rapidly in communities, particularly in settings where children are in close contact with each other, such as child care centers and schools. The infection is usually self-limiting and resolves within a few days, but severe cases can lead to dehydration and require hospitalization.

Prevention measures include good hygiene practices, such as handwashing with soap and water, safe disposal of feces, and rotavirus vaccination. The WHO recommends the inclusion of rotavirus vaccines in national immunization programs to reduce the burden of severe diarrhea caused by rotavirus infection.

Enterotoxigenic Escherichia coli (ETEC) is a type of diarrheagenic E. coli that causes traveler's diarrhea and diarrheal diseases in infants in developing countries. It produces one or two enterotoxins, known as heat-labile toxin (LT) and heat-stable toxin (ST), which cause the intestinal lining to secrete large amounts of water and electrolytes, resulting in watery diarrhea. ETEC is often transmitted through contaminated food or water and is a common cause of traveler's diarrhea in people traveling to areas with poor sanitation. It can also cause outbreaks in refugee camps, nursing homes, and other institutional settings. Prevention measures include avoiding consumption of untreated water and raw or undercooked foods, as well as practicing good personal hygiene.

cholera vaccine.. 2 Cholera vaccine. Your health care provider can give you more information.. The cholera vaccine used in the ... Cholera vaccine is a live, attenuated (weakened) Most travelers do not need cholera vaccine. If you vaccine which can be shed ... Cholera vaccine can prevent cholera.. Tell your vaccine provider if the person getting Cholera is spread through contaminated ... vaccine for you.. Cholera vaccine is not 100% effective against cholera and does not protect from other foodborne or waterborne ...
A cholera vaccine is a vaccine that is effective at preventing cholera. For the first six months after vaccination it provides ... "Vaxchora- cholera vaccine, live, oral kit". DailyMed. 24 October 2018. Retrieved 30 July 2020. "Vaxchora- cholera vaccine, live ... "Cholera Vaccine Information Statement". U.S. Centers for Disease Control and Prevention (CDC). October 2019. Cholera Vaccines ... The first cholera vaccines were developed in the late 1900s. They were the first widely used vaccine that was made in a ...
Recommendations of the Immunization Practices Advisory Committee Cholera Vaccine ... CHOLERA VACCINE Cholera vaccines *, whether prepared from Classic or El Tor strains, are of limited usefulness. In field trials ... Official name: Cholera Vaccine. SELECTED BIBLIOGRAPHY Bart KJ, Gangarosa EJ. Cholera. In: Kelley VC, ed. Brennemanns practice ... yellow fever and cholera vaccines ideally should be given at least 3 weeks apart. If that is not possible, and both vaccines ...
Vietnams Vaccine and Biomedical Product Company No. 1 (VaBiotech) has developed a new cholera vaccine that is superior to ... oral cholera vaccine for use in its public health program. The resulting vaccine had a 66 percent success rate, a good safety ... At US$1.25 per dose, MORACVAX is the worlds first cholera vaccine that is inexpensive enough for widespread use in the ... Since 1997, over 9 million doses of this first-generation vaccine have been used in Vietnam. In 2001, due to choleras ...
Cholera Vaccine, Live, for Oral Administration) may treat, side effects, dosage, drug interactions, warnings, patient labeling ... Vaxchora (Cholera Vaccine, Live, Oral) is a vaccine indicated for active immunization against disease caused by Vibrio cholera ... VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing ... Inform vaccine recipients that VAXCHORA is a live attenuated vaccine and has the potential for transmission of the vaccine ...
THE LIVE ATTENUATED ORAL CHOLERA VACCINE IS DERIVED FROM: V … ... FOR THE USE OF LYOPHILIZED CVD 103-HGR VACCINE (CVD 103-HGR) ( ... THE LIVE ATTENUATED ORAL CHOLERA VACCINE IS DERIVED FROM: Vibrio cholerae O1 and is administered in a single dose. Cholera is a ... ACIP recommends CVD 103-HgR, the only cholera vaccine licensed for use in the United States, for prevention of cholera among ... Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2022 MMWR Recomm Rep. 2022 Sep 30;71(2):1 ...
The global cholera vaccines market size was estimated at USD 63.1 million in 2017 and will exhibit a CAGR of 8.2% during the ... Cholera Vaccines Market Size, Share, Industry Trend Report 2018-2025. Cholera Vaccines Market Size, Share & Trends Analysis ...
Single Cholera Vaccine Dose May Slow Cholera Epidemics ... VOA News: Single Cholera Vaccine Dose May Slow Cholera ... "When it comes to a vaccine to prevent cholera, one dose may be as good as two. That is the finding of a new study whose authors ... Single Dose Of Cholera Vaccine Might Be Nearly As Effective As 2 Doses In Halting Outbreaks, Study Shows. Aug 27, 2015 ... Nearly 25% Of World Might Not Get COVID-19 Vaccine Until 2022; FDA Committee Considering Moderna Vaccine; Media Outlets Cover ...
Malawi secured a tranche of 2.9 million doses from the Gavi-supported Global oral Cholera Vaccine Stockpile in November. ... Malawis worst cholera epidemic in decades has sparked massive demand for vaccines but stocks are reportedly running low. ... Malawis worst cholera epidemic in decades has sparked massive demand for vaccines but stocks are reportedly running low.. ** ... A health worker takes a cholera vaccine at the Bwaila Hospital in Lilongwe central Malawi Wednesday, Jan. 11, 2023. - Copyright ...
HomeHealthLebanon has received its first batch of cholera vaccines. Lebanon has received its first batch of cholera vaccines. ... Lebanon has received its first batch of cholera vaccines as part of the international effort to help curb the spread of the ... The WHO, which recommends the use of cholera vaccines in line with other preventive measures such as the supply of clean water ... said earlier this month that the strained global supply of cholera vaccines prompted it to reduce the standard two-dose ...
... b will administer the second dose of oral cholera vaccine in five areas of Dhaka from August 3 to 10, under the supervision of ... Cholera Vaccinecholera vaccine drivedirectorate general of health servicesDGHSoral cholera vaccineDhakadisease preventive ... Administering 2nd dose of cholera vaccine from Aug 3 to 10 in Dhaka. ... Icddr,b will administer the second dose of oral cholera vaccine in five areas of Dhaka from August 3 to 10, under the ...
... the water we drink and the medicines and vaccines that treat and protect us. The Organization aims to provide every child, ... The region currently faces multiple emergencies including drought, Measles, Malaria, and a Cholera outbreak according to the ... Close to 1.9 million receive the Cholera vaccine despite challenging environment in Amhara region 20 November 2023. ... WHO recommends the use of cholera vaccines in combination with surveillance, water, sanitation and hygiene, social mobilization ...
... of oral cholera vaccines (OCV).. "We have oral cholera vaccines donated by Gavi. I have instructed the health ministry to act ... "My son was once a victim of cholera. The disease took a toll on him then. I am glad the government brought the oral vaccines, ... "My son was once a victim of cholera. The disease took a toll on him then. I am glad the government brought the oral vaccines, ... First came the floods... then came the oral cholera vaccines Amid massive downpours, southern Laos health workers brace for ...
... TOPICS:American Chemical SocietyBacteriaCholeraInfectious ... Edible Cholera Vaccine - Made of Powdered Rice - Proves Safe in Phase 1 Human Trials ... Current cholera vaccines contain killed or weakened V. cholerae bacteria and are administered orally. They offer the lowest ... Be the first to comment on New Type of Cholera Vaccine May Offer Much Longer-Lasting Protection. ...
... is the only vaccine available in the United States for protection against cholera. The vaccine is a live, attenuated oral ... vaccine that is given as a single dose. It is made from a strain of Vibrio cholerae that is not harmful and does not cause ... cholera vaccine recombinant live oral) is the only vaccine available in the United States for protection against cholera. The ... Cholera Vaccine Vaxchora (Recombinant Live Oral) Single-dose 100mL **Refrigerated Item by Emergent Travel Health Inc ...
... has supported the Minister of Public Health of Lebanon to secure a critical shipment of 600 000 doses of cholera vaccine from ... the International Coordination Group (ICG) managing the global supply of cholera vaccines. ... managing the global supply of cholera vaccines.. The vaccines were delivered to the Ministry of Public Healths Central Drug ... "Cholera vaccines are a critical tool to protect people and limit the spread of the outbreak, but they are not the only tool we ...
U.S. cholera vaccine market by product. 6.2.2.2. U.S. cholera vaccine market by end user. 6.2.2.3. Canada cholera vaccine ... UK cholera vaccine market by product. 6.3.2.6. UK cholera vaccine market by end user. 6.3.2.7. Italy cholera vaccine market by ... Rest of LAMEA cholera vaccine market by end user. 6.5.3. LAMEA cholera vaccine market, by product. 6.5.4. LAMEA cholera vaccine ... Canada cholera vaccine market by end user. 6.2.2.5. Mexico cholera vaccine market by product. 6.2.2.6. Mexico cholera vaccine ...
Probiotic Vaccines Could Be The Cholera Prevention Breakthrough Humanity Has Been Waiting For ... Probiotic Vaccines Could Be The Cholera Prevention Breakthrough Humanity Has Been Waiting For. ... "Probiotic Vaccines Could Be The Cholera Prevention Breakthrough Humanity Has Been Waiting For". ... both these new vaccine candidates could help meet the World Health Organizations goal of reducing cholera deaths by 90 percent ...
... between the level of vaccine coverage in an individuals social network and the incidence of cholera in individual vaccine ... we found incidence rates of cholera among placebo recipients were inversely related to levels of vaccine coverage (5.28 cases ... Receipt of vaccine by an individual and the level of vaccine coverage of the individuals social network were independently ... data from a placebo-controlled trial of B subunit-killed whole-cell and killed whole-cell-only oral cholera vaccines in ...
Dukoral suspension and effervescent granules for oral suspension, Cholera vaccine (inactivated, oral) *. Pharmacy Only: ... Dukoral suspension and effervescent granules for oral suspension, Cholera vaccine (inactivated, oral) ...
... a room-temperature stable oral vaccine being developed using genetically modified rice plants. ... KR: How does the MucoRice-CTB vaccine differ from other available vaccines for cholera?. HK: Existing cholera vaccines are a ... Thus, MucoRice-CTB is a cold-chain free vaccine.. Since oral cholera vaccines formulated from killed V. cholerae are already ... Currently, there are several different needle-free vaccines available to prevent for cholera, made from live-attenuated or " ...
Dukoral suspension and effervescent granules for oral suspension, Cholera vaccine (inactivated, oral) *. Pharmacy Only: ... Dukoral suspension and effervescent granules for oral suspension, Cholera vaccine (inactivated, oral) ...
Vaccines for rotavirus and cholera have the potential to reduce diarrhea morbidity and mortality burden. But there is no ... The estimated effect of cholera, shigella, Enterotoxigenic Escherichia coli (ETEC) and rotavirus vaccines was determined by ... reduction in cholera incidence due to their respective vaccines. We did not find sufficient evidence and a suitable outcome to ... A total of 24 papers were selected and analyzed for all the four vaccines. Based on the evidence, we propose a 74% mortality ...
IVI and EuBiologics sign memorandum of understanding with DEK Vaccines Limited to support fill and finish of oral cholera ... IVI and EuBiologics sign memorandum of understanding with DEK Vaccines Limited to support fill and finish of oral cholera ... IVI and EuBiologics sign memorandum of understanding with DEK Vaccines Limited to support fill and finish of oral cholera ... IVI developed the worlds first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and ...
"Introduction to the cholera vaccine session" 202202, no. 11 (2022). Sanchez, Pablo "Introduction to the cholera vaccine session ... Influenza vaccines for older adults Cite CITE. Title : Influenza vaccines for older adults Personal Author(s) : Groskopf, Lisa ... Seasonal influenza vaccines Cite CITE. Title : Seasonal influenza vaccines Personal Author(s) : Talbot, H. Keipp Corporate ... Cholera Vaccine Work Group. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2022 ...
In our country, Cholera disease burden consists of both cholera outbreaks and endemic cholera comprising at least 300,000 ... Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine. The safety and scientific validity of this ... Knowledge gap: The WHO recommends OCV for use in both endemic and epidemic cholera settings4. At present there are two vaccines ... Objectives: The objective of this study is to determine most safe and immunogenic formulation for new oral cholera vaccine HL- ...
Cholera Vaccine. *Introduction pdf icon[4 pages]. Dr. P Sanchez. *Vaxchora pediatric dose development pdf icon[12 pages]. Dr. J ... Influenza Vaccines. *Introduction pdf icon[4 pages]. Dr. K Talbot. *Influenza vaccines for older adults pdf icon[65 pages]. Dr ... Hepatitis B Vaccines. *Introduction pdf icon[3 pages]. Dr. K Ault. *Safety & immunogenicity of a 3-Antigen hepatitis B vaccine ... EtR for TBE vaccine use among laboratory workers pdf icon[17 pages]. Dr. S Hills ...
We prepared GBS capsular polysaccharide (CPS) - recombinant cholera toxin B subunit (rCTB) conjugate vaccines by different ... Group B streptococcus capsular polysaccharide - Cholera toxin B subunit conjugate vaccine for mucosal immunisation : ... An optimally effective GBS vaccine should induce both mucosal and systemic immunity. ... development and preclinical evaluation of experimental conjugate vaccines. Abstract. Group B streptococci (GBS) can colonize ...
The Generating evidence for decision-making on the use of the oral cholera vaccine from Wellcome Trust supports ... Home » Grants » Generating evidence for decision-making on the use of the oral cholera vaccine (worldwide) ... The Generating evidence for decision-making on the use of the oral cholera vaccine from Wellcome Trust supports ... Generating evidence for decision-making on the use of the oral cholera vaccine (worldwide). ...

No FAQ available that match "cholera vaccines"

No images available that match "cholera vaccines"